# Sources — Wilma Mankiller

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 6, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Wilson LD. “Mankiller, Wilma Pearl (1945–2010).” *The Encyclopedia of Oklahoma History and Culture*, Oklahoma Historical Society. Supports her birth “on November 18, 1945, in Tahlequah, Oklahoma,” as “the sixth of eleven children,” her father “full blood Cherokee”; the family's move to San Francisco in 1957; Alcatraz in 1969 as a catalyst; her return to eastern Oklahoma two years after her divorce in 1974; deputy chief from August 1983, principal chief from December 1985, re-elected in 1991, serving until 1995; her autobiography *Mankiller: A Chief and Her People* (1993) with Michael Wallis and the quotation “we have indigenous solutions to our problems”; the Presidential Medal of Freedom (1998); her home on her grandfather's allotment, Mankiller Flats, in Adair County; and her death on April 6, 2010. https://www.okhistory.org/publications/enc/entry?entry=MA013
2. Brando E. “Wilma Mankiller (1945–2010).” National Women's History Museum. Supports her birth in Tahlequah, “the capital of the Cherokee Nation”; the move to San Francisco at 11, described by her as “my own little Trail of Tears”; principal chief from 1985 for ten years; the Presidential Medal of Freedom in 1998; and that she “died on April 6, 2010 at age 64 from pancreatic cancer.” https://www.womenshistory.org/education-resources/biographies/wilma-mankiller
3. “Mankiller, Wilma (b. 1945).” *Encyclopedia of the Great Plains*, University of Nebraska–Lincoln. Supports her return to Mankiller Flats in 1977; “a near-fatal car accident in 1979” in which her best friend was killed in a head-on collision on a blind curve; that her “recovery was compounded by the emotional trauma” of the friend's death and “the onset of myasthenia gravis”; that “with help from Cherokee medicine people, surgery, and drug therapy, Mankiller fully recovered”; the 1991 election “a year after repeated hospitalizations and a kidney transplant”; and that “a second kidney operation and treatment for lymphatic cancer” led her to decline a third term in 1995. https://plainshumanities.unl.edu/encyclopedia/doc/egp.na.062.html
4. *Cherokee Phoenix*, March 3, 2010. “Ex-Cherokee chief Mankiller diagnosed with cancer.” Supports the announcement of advanced pancreatic cancer and her statement that she was “mentally and spiritually prepared for this journey”; that “a 1979 car accident nearly claimed her life and resulted in 17 operations,” that she had myasthenia gravis and “underwent a kidney transplant in 1990,” and had “battled lymphoma and breast cancer”; and a Cherokee Nation release giving her birthplace as W.W. Hastings Indian Hospital in Tahlequah. https://www.cherokeephoenix.org/news/ex-cherokee-chief-mankiller-diagnosed-with-cancer/article_f9200009-41a4-5155-85e4-c4e70b946f51.html
5. *News On 6* (Tulsa), February 17, 2000. “Fighting for her people, her health.” Supports that she “survived a head-on car crash in 1979” and “less than a year later, while still dealing with the physical and mental trauma of the accident, she was diagnosed with myasthenia gravis”; that “in 1990, hereditary polycystic kidney disease — ‘my old nemesis’ — necessitated a transplant” with a kidney from her brother; that it “was damaged by her 1996 treatment for lymphoma”; the “second kidney transplant in 1998”; and that “last year, she was treated for breast cancer.” https://www.newson6.com/story/5e3685f62f69d76f6209b825/fighting-for-her-people-her-health
6. *The Daily Beast*, April 6, 2010, summarizing the Associated Press obituary. Supports that she “survived a 1979 car crash that required 17 surgeries, a muscular disorder called myasthenia gravis, and a kidney transplant in 1990.” https://www.thedailybeast.com/cherokee-ex-chief-wilma-mankiller-dies/
7. Oklahoma Hall of Fame. “Wilma Mankiller” (inducted 1994). Supports that “in 1978 Mankiller was told she would never walk again after an automobile accident shattered her legs, broke her ribs, and crushed her face,” that after 17 operations she “became stricken with the neuromuscular disease myasthenia gravis,” that she became a spokesperson for the Myasthenia Gravis Foundation, that she returned to work with the Cherokee Nation in 1981, and gives her birthplace as Rock Mountain in Adair County. https://www.oklahomahof.com/hof/inductees/mankiller-wilma-1994
8. *UXL Encyclopedia of World Biography* (Gale, via Encyclopedia.com). “Mankiller, Wilma.” Supports “almost twenty operations,” that “her leg was barely saved from amputation,” and that “in 1980, Mankiller came down with myasthenia gravis.” https://www.encyclopedia.com/social-sciences/news-wires-white-papers-and-books/mankiller-wilma
9. Good Voice C. “Former Cherokee Nation Chief Wilma Mankiller dies.” *Cherokee Phoenix*, April 6, 2010. Supports that she “died in the morning hours of April 6 at her home in rural Adair County,” aged 64, and the March 2 announcement of “stage 4 metastatic pancreatic cancer.” https://www.cherokeephoenix.org/news/breaking-news-former-cherokee-nation-chief-wilma-mankiller-dies/article_4b41b53d-5f8e-5ed7-96e7-7ea1b90c685a.html
10. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology* 2021;96(3):114-122 (PMID 33144515; full text PMC7884987): thymectomy “should be considered early in the disease” in non-thymomatous AChR antibody-positive generalized MG aged 18 to 50, as an elective procedure “when the patient is stable”; no indication for thymectomy in MuSK-positive disease; eculizumab “after trials of other immunotherapies have been unsuccessful”; meningococcal vaccination before complement inhibition. https://pubmed.ncbi.nlm.nih.gov/33144515/
2. Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 2016;87(4):419-425 (PMID 27358333): pyridostigmine, glucocorticoids, steroid-sparing agents, treatment goals (minimal manifestation status) and crisis care. https://pubmed.ncbi.nlm.nih.gov/27358333/
3. Wolfe GI, et al. Randomized Trial of Thymectomy in Myasthenia Gravis (MGTX). *N Engl J Med* 2016;375(6):511-522 (PMID 27509100). https://pubmed.ncbi.nlm.nih.gov/27509100/
4. Howard JF Jr, et al. Efgartigimod in generalised myasthenia gravis (ADAPT). *Lancet Neurol* 2021;20(7):526-536 (PMID 34146511). https://pubmed.ncbi.nlm.nih.gov/34146511/
5. Myasthenia Gravis Foundation of America. “Cautionary Drugs”: telithromycin, fluoroquinolones, macrolides, aminoglycosides, magnesium by vein, beta-blockers, statins and others. https://myasthenia.org/living-with-mg/mg-emergency-preparedness/cautionary-drugs/
6. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease. *Kidney Int* 2025;107(2S):S1-S239 (PMID 39848759; full text read from the White Rose repository): Recommendation 2.1.3 (age 18 to 49, CKD G1 to G2 and BP above 130/85: target 110/75 mm Hg or lower by home monitoring, 1D); Practice Point 2.1.4 (individualized approach for BP below 130/85); RAS inhibition as the cornerstone of drug treatment; the Mayo Imaging Classification of height-adjusted total kidney volume; Recommendation 4.1.1.1 (tolvaptan for rapidly progressive disease); Recommendation 4.2.1.1 (2 to 3 liters of water a day). https://pubmed.ncbi.nlm.nih.gov/39848759/
7. Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheumatol* 2023;75(12):2088-2102 (PMID 37845798): fracture-risk assessment with bone density soon after starting glucocorticoids expected to last more than three months. https://pubmed.ncbi.nlm.nih.gov/37845798/
8. Cherokee Nation Health Services. https://health.cherokee.org/
9. U.S. Preventive Services Task Force: A and B recommendations, cervical cancer (2018), depression (2023), intimate partner violence (2018), hepatitis C (2020), HIV (2019) and folic acid (2023); CDC Adult Immunization Schedule by Medical Condition and Other Indication; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations; https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html; https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Sources.** The history rests on the Oklahoma Historical Society encyclopedia, the National Women's History Museum, the *Encyclopedia of the Great Plains*, the Oklahoma Hall of Fame, Encyclopedia.com, *News On 6* (2000), *The Daily Beast*'s summary of the AP obituary, and two *Cherokee Phoenix* reports (2010). Her autobiography *Mankiller: A Chief and Her People* was not read directly and is cited only as quoted by the Oklahoma Historical Society. The *New York Times* obituary (paywalled; a reprint site returned an error) and the Cherokee Nation biography page (its text did not load) were not used. Wikipedia was not used.
- **Recent-death rule.** She died in 2010, so the rule applies. The record uses only what she made public and what obituaries and reference works reported. No sick visit is added. The emotional trauma after the crash (CLM-0006) is marked sensitive and recorded only as published; no mental health diagnosis is made, and the modern mood screens are synthetic and below the threshold for a safety assessment. Nothing in the modern episode adds an illness beyond those documented: blood pressure is kept normal-high without a hypertension diagnosis, and kidney function and urine albumin are normal.
- **Living people and relatives.** Her husband, daughters and brother are not named, and none is given a statement, decision or health fact; the kidney donor appears only as “her brother” in the documented claim. Her parents are named in the sources but not here. The friend killed in the crash, named in a source, is not named here. Living public figures named in the sources (a friend at her funeral, her predecessor as chief, officials) are not named. Her daughters appear in the modern episode only as members of her household, with no role in her care; her health care agent is unnamed. No other figure with a record is named, so identity.historical_mentions is not used. The word in one source about her mother's ancestry is not used, because it matches another record's alias.
- **Name and alias.** The alias is her full name, Wilma Pearl Mankiller (Oklahoma Historical Society), which appears in no other record. The display name splits simply, so identity.name_parts is not used. The notes call her Ms. Mankiller.
- **Conflicts recorded.** The crash is dated 1979 in most sources and 1978 by the Oklahoma Hall of Fame; 1979 is used. Her birthplace is Tahlequah in most sources (W.W. Hastings Indian Hospital in a Cherokee Nation release) and Rock Mountain in Adair County in the Hall of Fame; Tahlequah is used. The move to San Francisco is 1956 or 1957, and her return to Oklahoma 1976 or 1977. Lymphoma treatment is dated 1996 by *News On 6*, while the Great Plains encyclopedia links lymphatic cancer treatment and a second kidney operation to her 1995 decision not to run again. The Daily Beast gives her term as 1985 to 1996; the Oklahoma Historical Society gives 1995, which is used.
- **Corrections to the brief.** (1) The brief asked whether a thymectomy was documented. The sources say surgery helped her recovery from myasthenia gravis but do not name the operation, so no historical thymectomy is recorded; the modern episode's thymectomy is synthetic. (2) The brief gave the death as at her home in Adair County; the *Cherokee Phoenix* confirms “her home in rural Adair County.” (3) Breast cancer is dated 1999 only through a February 2000 article saying “last year.” (4) The polycystic kidney disease is described in the sources as hereditary; the autosomal dominant (adult) type, Q61.2, is an inference recorded in the claim.
- **Index age and dates.** The index visit on March 9, 2026 maps to March 9, 1980, when she was 34, in the year that one source dates her myasthenia gravis and less than a year after the 1979 crash (the month of the crash is not recorded). The synthetic date of birth is November 18, 1991, a shift of 46 years. The visits on March 23, May 4, July 13, August 24 and October 12, 2026, and the synthetic thymectomy on June 8, map to the same days of 1980, before her 35th birthday; she returned to work in 1981. The presenting pattern is used: ptosis, diplopia and fatigable weakness are a resolved problem (H53.2) at the second visit, when antibodies and nerve stimulation establish generalized MG (G70.00). The intake documents show only that MG is suspected; the claim about her diagnosis is linked to the 1981 return to work, so the intake H&P does not show it.
- **Treatment choices.** (1) Pyridostigmine 30 mg three times daily as a trial at intake, 60 mg four times daily at diagnosis, three times daily at seven months. (2) Prednisone started at 10 mg and raised weekly to 40 mg to avoid early worsening, held through thymectomy, then tapered by 5 mg every two to three weeks. (3) Azathioprine rather than mycophenolate because she is of childbearing age, after TPMT activity and hepatitis B and tuberculosis screening (results recorded in the notes, not as coded observations). (4) Early robotic extended thymectomy at 34 for AChR antibody-positive generalized MG without thymoma (MGTX; 2020 guidance); pathology thymic hyperplasia (synthetic). (5) Efgartigimod and complement inhibitors kept in reserve; the disease was not refractory. (6) Pneumocystis prophylaxis with trimethoprim-sulfamethoxazole while prednisone was 20 mg or more with azathioprine, a common practice threshold that the owner may review. (7) PCV20 and recombinant zoster vaccine before immunosuppression; inactivated vaccines only afterwards. MuSK antibodies and single-fiber EMG were not needed. The MG-ADL score has no LOINC code, so it is given in the notes.
- **Kidney care.** The documented hereditary polycystic kidney disease is staged synthetically: normal eGFR and urine albumin, kidneys enlarged with many cysts, height-adjusted total kidney volume 364 mL/m (Mayo Imaging Class 1B, not rapidly progressive), so tolvaptan is not indicated. Home blood pressure stayed below 130/85, so under KDIGO Practice Point 2.1.4 no medicine was started; the 110/75 target would apply if readings rose above 130/85, and a beta-blocker would be avoided because of MG. Water 2 to 3 liters a day, less salt, and no NSAIDs. No statement is made about which relatives had the disease.
- **Culturally safe care.** Laboratory work is arranged at a Cherokee Nation Health Services clinic near her home, with results shared; she is given time to understand each step; her own Cherokee medicine is respected, anchored to the documented help of Cherokee medicine people in her recovery, and no practice or ceremony is described; she is asked only to share any plant medicine so that interactions can be checked. Her words about “indigenous solutions to our problems” are quoted only as published. Nothing is claimed about Cherokee or Native patients in general.
- **Protocol deviation.** The blood count and liver tests due two, four and six weeks after azathioprine started were not done: the orders were placed at this clinic, she was preparing for surgery an hour's drive away, and no one followed up. The ten-week tests showed no toxicity, so no harm resulted. Corrective action: standing orders at the Cherokee Nation clinic near her home with a nurse call for each result (INT-011); the later checks were done on time.
- **Synthetic clinical picture.** Everything in the modern episode is synthetic: the symptoms, examination, every laboratory value, the antibody level, nerve stimulation, CT, ultrasound and DXA, the thymectomy and its pathology, the scores (PHQ-9, PHQ-2, MG-ADL, AUDIT-C), medicines and outcomes. Height (163 cm) and weights are synthetic. Reference ranges are typical adult female ranges.
- **Preventive visit.** A periodic adult preventive visit at 34 (CPT 99395 and 99497 in plain text), eleven weeks after thymectomy. Judgment calls: recombinant zoster dose 2 that day; influenza and COVID-19 at the seven-month visit; HIV and hepatitis C screening once; cervical screening shown as up to date (synthetic), with the interval to be reviewed on long-term immunosuppression; no live vaccines; HPV vaccine not wanted; contraception recorded only as “a reliable method, not recorded here”; advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (two weeks with the consultation, six weeks, five weeks after thymectomy, and seven months) are documented as focused visits on the 2016 and 2020 international MG guidance, KDIGO 2025 and ACR 2022. Synthetic findings introduced: MG-ADL falling from 7 to 1 (minimal manifestation status), FVC from 3.25 to 3.62 L, white cells rising on prednisone, a normal DXA, and hemoglobin A1c rising from 5.3 to 5.6 percent. The one deviation is the missed early azathioprine tests above.
- **Consultation.** The neuromuscular neurology referral and the consultation by Marcus Okafor-Delaney, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the six referral questions in line with what the record shows afterwards: generalized AChR antibody-positive MG without thymoma; pyridostigmine and prednisone started low and raised slowly; azathioprine after screening; early robotic thymectomy once stable; newer targeted therapies in reserve; and the crisis signs, medicines to avoid and kidney considerations.
